CELC

AI Memo

Celcuity

As of 2026-10-17/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-17 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

VIKTORIA-1 data at ESMO • 2026-10-24

Base target: $60 / p=50% prob

Biggest risk

Availability does not establish paid demand. Launch spending is rising: Q2 2026 SG&A was $35.0 million versus $7.6 million a year earlier, while operating cash use was $55.4 million. Safety, access, competitive treatment choices, and FDA review could limit the payoff. Celcuity Q2 release

Invalidation

Break below $38 or thesis failure.

What would change my mind?

FDA approval for the wild-type indication, confirmed commercial availability, and the submitted mutant sNDA establish a more tangible opportunity than a purely clinical-stage thesis. At June 30, Celcuity reported $754.0 million in cash, equivalents, and short-term investments and expected funding at least into 2029. [#SEC-8K-2026-08-13] Celcuity Q2 release

Research note

Recommendation

—

Confidence

medium

As of

2026-10-17

Base target

$60

p=50%

Bull target

$80

p=25%

Bear target

$38

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Evidence of REVTORPYK launch uptake
VIKTORIA-2 first-line development
FDA approval for the wild-type indication, confirmed commercial availability, and the submitted mutant sNDA establish a more tangible opportunity than a purely clinical-stage thesis.

BearKey bullets

Q2 commercial spending and operating cash use increased; the company's runway expectation depends on future spending and launch execution.
Celcuity Q2 release
REVTORPYK is commercially available, but verified paid uptake, payer access, and prescribing figures were unavailable in the checked sources.

WatchKey bullets

VIKTORIA-1 data at ESMO

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $60 (p=50%)

Target spread vs base: +33% / -37%

Scenario probabilities

Bull Target: $80 (p=25%)Base Target: $60 (p=50%)Bear Target: $38 (p=25%)

Commentary

Company news is constructive, but the July approval, August sNDA submission, and September commercial availability are already public. CELC closed at $56.58 on October 16, down 6.17% that session and well below the prior baseline's $77.38 September 29 anchor; the checked coverage did not establish a cause for the decline. October 16 price record The numeric sentiment fields are unavailable-data placeholders, not neutral readings. Verified launch sales and recent analyst estimate revisions remain unavailable.

As of 2026-10-17 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Evidence of REVTORPYK launch uptake
VIKTORIA-2 first-line development

Scenarios

Bull Target (Scenario probability)

$80 / p=25% prob

Base Target (Scenario probability)

$60 / p=50% prob

Bear Target (Scenario probability)

$38 / p=25% prob

Analysis 2026-10-17 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-10-24
VIKTORIA-1 data at ESMO
Celcuity has scheduled updated PIK3CA-mutant cohort analyses for October 24. The presentation could change confidence in the pending label expansion, but favorable new findings are not assured. [#SEC-8K-2026-08-13] Celcuity ESMO announcement
Prob 55.00% • Move 10.00% • Priced-in 60.00%
EVENT2027-06-30
FDA review of PIK3CA-mutant expansion
Celcuity submitted the REVTORPYK sNDA on August 26, supported by VIKTORIA-1 results. FDA review and a decision remain uncertain; the date shown is a monitoring horizon, not an announced decision date. Celcuity sNDA announcement
Prob 60.00% • Move 15.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

Evidence of REVTORPYK launch uptake
2026-12-31
Celcuity confirmed U.S. commercial availability on September 30; launch itself is no longer prospective. Prescribing, reimbursement, and paid sales remain the decision-relevant tests, with no verified uptake figures in the checked sources. [#SEC-8K-2026-08-13] Celcuity launch announcement
Prob 60% • Move 12% • Priced-in 45%

Long-term Catalysts

Months to a year

VIKTORIA-2 first-line development
2027-12-31
The ongoing Phase 3 program includes separate endocrine-resistant and endocrine-sensitive first-line studies. Enrollment and eventual efficacy and safety results could broaden the opportunity, but no readout date was confirmed; this is an illustrative monitoring horizon. [#SEC-8K-2026-08-13] Celcuity Q2 release
Prob 45% • Move 18% • Priced-in 30%

Risks

Q2 commercial spending and operating cash use increased; the company's runway expectation depends on future spending and launch execution. Celcuity Q2 release
REVTORPYK is commercially available, but verified paid uptake, payer access, and prescribing figures were unavailable in the checked sources. Celcuity launch announcement
REVTORPYK's stated safety warnings include severe stomatitis and rash, which may affect treatment persistence or adoption. Celcuity sNDA announcement
The PIK3CA-mutant sNDA remains subject to FDA review; submission is not approval. Celcuity sNDA announcement

Peers

Symbol	Summary
AZN	AstraZeneca's Truqap serves an overlapping biomarker-selected breast-cancer population. Its diversified scale makes its corporate valuation a poor direct CELC comparable. AstraZeneca approval announcement
NVS	Novartis's Piqray addresses PIK3CA-mutant HR+/HER2- advanced breast cancer, making it a therapeutic comparator for the proposed label expansion, not a size or valuation peer. Novartis product announcement

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-17

Loading AI feed…

Symbol

Summary

AZN

AstraZeneca's Truqap serves an overlapping biomarker-selected breast-cancer population. Its diversified scale makes its corporate valuation a poor direct CELC comparable. AstraZeneca approval announcement

NVS

Novartis's Piqray addresses PIK3CA-mutant HR+/HER2- advanced breast cancer, making it a therapeutic comparator for the proposed label expansion, not a size or valuation peer. Novartis product announcement